The Response Evaluation Criteria in Solid Tumors (RECIST)

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations

Abstract

Cancer is one of the most dominant global health concerns, and the field of cancer therapeutics is in an era of rapid expansion. It is thus critical that the system for evaluating the effectiveness of new cancer treatments be accurate, standardized, and applied to clinical research across healthcare systems. RECIST is a set of published rules that define when cancer patients with solid tumors “respond, " “stabilize, " or “progress” during treatments. Below is a summary of the current guidelines for the assessment of tumor response to antineoplastic therapies including special considerations such as evaluation of immune therapies and malignancies involving the central nervous system. Also reviewed are different assessment techniques and the rationalization of standardization of assessment systems.

Original languageEnglish (US)
Title of host publicationPredictive Biomarkers in Oncology
Subtitle of host publicationApplications in Precision Medicine
PublisherSpringer International Publishing
Pages501-511
Number of pages11
ISBN (Electronic)9783319952284
ISBN (Print)9783319952277
DOIs
StatePublished - Jan 1 2018

Keywords

  • iRECIST
  • PERCIST
  • RANO-BM
  • RECIST
  • Tumor assessment
  • Tumor measurement

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'The Response Evaluation Criteria in Solid Tumors (RECIST)'. Together they form a unique fingerprint.

Cite this